The Korean powder that stops severe bleeding in one second

Introduction: a discovery that could change emergency medicine

A problem as old as military medicine

Massive bleeding remains one of the leading causes of preventable death on battlefields, in traffic accidents, and in natural disasters, a problem that standard dressings often struggle to solve when a wound is deep, irregular, or hard to reach. A team of South Korean researchers says it has developed a radically different solution.

Scientists at the Korea Advanced Institute of Science and Technology, better known by the acronym KAIST, have developed a hemostatic spray powder capable of forming a powerful gel barrier in roughly one second after being applied to a wound (Medical Xpress).

A multidisciplinary team, including an active-duty officer

The project was jointly led by professor Steve Park, of the department of materials science and engineering, and professor Sangyong Jon, of the department of biological sciences, with the notable involvement of an active-duty major in the South Korean army as part of the research team (WION). This makeup reflects the project's explicitly military ambition from the outset.

The results of this research were published in the scientific journal Advanced Functional Materials, a mark of rigor since the study went through peer review before its official publication on December 29, 2025 (informat.ro).

How this powder, called AGCL, works

Clever chemistry built on natural materials

The powder, named AGCL, combines three biocompatible components: alginate and gellan gum, which react with the calcium present in blood to quickly form a gel, along with chitosan, which binds to blood components to reinforce chemical and biological hemostasis (Medical Xpress). This combination allows for both a physical and a chemical action on the wound.

On contact with cations such as calcium present in blood, the powder turns into a gel state within one second, instantly sealing the wound. This chemical reaction, called ionic gelation, does not turn the entire blood supply into gel, but instead creates a localized barrier right at the wound site (fact-check published on social media).

Impressive absorption capacity

Thanks to an internal three-dimensional structure, this powder can absorb up to seven times its own weight in blood, roughly 725%, which allows it to quickly stop blood flow even in cases of excessive, high-pressure bleeding (Medical Xpress). This performance far exceeds that of hemostatic agents currently available commercially.

The resulting gel also shows an adhesive strength above 40 kilopascals, a pressure level sufficient to withstand firm manual pressure, an essential technical criterion for field use in often chaotic conditions (Medical Xpress).

Encouraging results in animal trials

A measurable reduction in blood loss

In surgical trials involving liver injuries, the AGCLpowder significantly reduced blood loss and shortened the time needed to stop the bleeding, compared with existing commercial hemostatic agents already used in clinical settings (WION). Liver function in the tested subjects returned to normal within two weeks of the surgical procedure.

No signs of systemic toxicity were detected during these trials, an encouraging result for the technology's continued development ahead of possible clinical trials on human subjects (WION).

A safety profile that reassures researchers

Lab tests revealed a hemolysis rate below 3%, cell viability above 99%, and antibacterial efficacy reaching 99.9%, figures that suggest a solid safety profile for this new generation of hemostatic agent (WION). These preliminary results will still need to be confirmed through rigorous clinical trials before any widespread use in humans.

The powder also retains its effectiveness for roughly two years at room temperature, with no refrigeration required, a major logistical advantage for rapid deployment on military operational theaters or in remote disaster zones (informat.ro).

Intended applications, from the battlefield to the emergency room

A stated priority for the military context

The research team explicitly designed this technology to improve the survival odds of wounded combatants, a focus reinforced by the presence of an active-duty service member within the research project itself. The goal is to give military doctors and first responders a faster, more reliable tool than traditional compression and dressing methods (WION).

On a battlefield, every second saved in controlling bleeding can mean the difference between life and death, particularly when medical evacuation can take time in active conflict zones such as those seen in Ukraine in recent years.

An equally significant civilian potential

Beyond the military context, researchers envision applications in civilian emergency medicine, notably for paramedics, hospital emergency services, and potentially, eventually, first-aid kits for the general public (New York Post). This versatility could democratize effective control of severe bleeding well beyond strictly military settings.

The ease of use, summed up by the researchers themselves as aim, spray, seal, could allow minimally trained responders to correctly apply the treatment in high-stress emergency situations.

What this means for first responders

A potentially decisive time saving

For first responders, whether military doctors, paramedics, or volunteer rescuers, the ease of applying this powder could considerably reduce the time needed to stabilize a victim before transport to a specialized medical facility. Unlike traditional compression dressings, which often require several minutes of sustained application, this technology promises near-instant action.

This speed of action could prove especially valuable in mass-casualty triage situations, such as terrorist attacks, natural disasters, or armed conflicts involving large numbers of simultaneous casualties, where every minute saved per patient can literally save additional lives.

Minimal training required for effective use

One of the most compelling arguments in favor of this technology lies in its ease of use, which does not require extensive medical training to apply correctly, unlike certain suturing or specialized compression techniques that demand significant clinical expertise.

This accessibility could democratize the control of severe bleeding, particularly in regions where access to qualified medical personnel remains limited, a public health issue especially relevant in rural areas or prolonged conflict settings.

The limits and questions that remain open

No confirmed commercialization date

Despite the enthusiasm sparked by this discovery, the research organization has not yet revealed a precise timeline for the commercial availability of this hemostaticpowder, leaving uncertainty about how long it will take before it becomes accessible to healthcare professionals or the general public (New York Post).

The move from animal trials to clinical trials on human subjects is generally a long and costly step, subject to strict regulatory requirements that can take several years to reach official approval.

Scientific precedents that call for caution

Other innovative hemostatic agents, developed by research teams around the world and published in journals indexed on PubMed, have also shown promising laboratory results without necessarily translating into widespread clinical adoption, a useful reminder that laboratory innovation does not automatically guarantee large-scale commercial or medical success.

The researchers themselves acknowledge that further trials will be needed to confirm the safety and effectiveness of this technology under real clinical conditions, beyond the controlled environments of the animal trials conducted so far.

Reactions from the international medical community

A generally positive but cautious reception

Several emergency medicine experts, cited in various international reports since the initial publication, praise the originality of the chemical approach used by the KAIST team, while noting that the path from animal trials to human clinical application remains fraught with considerable regulatory and scientific hurdles.

This measured reception reflects a healthy scientific culture, where enthusiasm for a promising discovery must never eclipse the need to rigorously validate every step before widespread clinical adoption worldwide.

Growing interest from Western armed forces

Specialized publications in military medicine have also noted this Korean breakthrough, suggesting that Western armies could eventually take an interest in equipping their own combat medical units, provided clinical trials confirm the safety and effectiveness observed in preliminary animal trials.

This potential military interest underscores the strategic importance of this kind of medical innovation, which extends well beyond a strictly scientific framework to touch on national security considerations and preparedness for future conflicts.

The broader context of South Korean medical innovation

A healthcare industry in full expansion

South Korea has been investing heavily in biomedical research for several years, positioning institutions like KAIST among the world's reference centers for innovation in materials science applied to health. This discovery fits into a broader trajectory of Korean technological breakthroughs gaining growing international recognition.

The funding behind this research, combining academic expertise with direct military interest, also illustrates a collaboration model that could inspire other Western countries looking to accelerate the transfer of technology from the lab to the operational field.

An increasingly fierce international competition

Several research teams around the world, notably in the United States and Europe, are also working on next-generation hemostatic agents, often inspired by similar biological mechanisms involving natural polymers and rapid gelation reactions. This international scientific competition ultimately benefits patients, by accelerating the pace of discoveries.

Publication in an internationally recognized peer-reviewed journal also allows other research teams to verify, reproduce, and potentially improve this technology, an essential scientific process before any widespread clinical adoption.

Conclusion: a promising advance that still has to prove itself

What this discovery really represents

The hemostatic powder developed by researchers at KAIST represents a real and well-documented technical advance in controlling severe bleeding, with solid preliminary data on its effectiveness and safety in an experimental animal setting. Its ability to act within one second on deep, irregular wounds fills a therapeutic gap long recognized by the emergency medical community.

This innovation also illustrates the value of Korean scientificresearch in the biomedical field, a sector where international competition, notably with Western and Chinese labs, is intensifying rapidly.

The road still ahead before widespread use

Before this technology can concretely save lives on battlefields or in emergency rooms, it will need to pass through the rigorous stages of human clinical trials, obtain the necessary regulatory approvals, and prove its viability under large-scale industrial production conditions.

It would be premature to promise an immediate revolution in emergency medicine, but this discovery certainly deserves close monitoring by the international scientific and medical community in the months and years ahead.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my acknowledged biases

I am a columnist, not a doctor or biomaterials researcher, and I rely on verified scientificpublications and journalistic reporting for this investigation. I have no ties to the KAISTresearch team or to the scientific journals cited, and I approach this discovery with measured enthusiasm rather than promising a medical miracle.

What I don't know and my method

I cannot personally assess the full technical validity of the data published in Advanced Functional Materials, nor predict with certainty the real commercialization timeline for this hemostaticpowder. My method consists of cross-referencing KAIST's official communications with independent journalistic reporting and fact-checks published online, clearly flagging the limits of what current data allows me to state.

Sources

Primary sources

Medical Xpress — New sprayable powder forms instant gel barrier to stop severe bleeding, December 29, 2025

informat.ro — New hemostatic agent developed for the rapid cessation of severe hemorrhages, January 6, 2026

Secondary sources

New York Post — South Korean scientists create life-saving spray to stop bleeding instantly, February 7, 2026

WION Podcast — A spray powder stops bleeding in one second, January 24, 2026

Fossbytes — Fact-check on the KAIST discovery

DBR — A KAIST major contributes to development of instant hemostatic spray, December 29, 2025